(3-Aminomethylphenyl)boronic
acid (AMPB)-installed
hyaluronic acid-
ceramide (HACE)-based nanoparticles (NPs), including
manassantin B (MB), were fabricated for
tumor-targeted delivery. The
amine group of AMPB was conjugated to the
carboxylic acid group of
hyaluronic acid (HA) via
amide bond formation, and synthesis was confirmed by spectroscopic methods. HACE-AMPB/MB NPs with a 239-nm mean diameter, narrow size distribution, negative zeta potential, and >90%
drug encapsulation efficiency were fabricated. Exposed AMPB in the outer surface of HACE-AMPB NPs (in the aqueous environment) may react with
sialic acid of
cancer cells. The improved cellular accumulation efficiency, in vitro antitumor efficacy, and
tumor penetration efficiency of HACE-AMPB/MB NPs, compared with HACE/MB NPs, in MDA-MB-231 cells (CD44 receptor-positive human breast
adenocarcinoma cells) may be based on the CD44 receptor-mediated endocytosis and
phenylboronic acid-
sialic acid interaction. Enhanced in vivo
tumor targetability, infiltration efficiency, and antitumor efficacies of HACE-AMPB NPs, compared with HACE NPs, were observed in a MDA-MB-231
tumor-xenografted mouse model. In addition to passive
tumor targeting (based on an enhanced permeability and retention effect) and active
tumor targeting (interaction between HA and CD44 receptor), the
phenylboronic acid-
sialic acid interaction can play important roles in augmented
tumor targeting and penetration of HACE-AMPB NPs. STATEMENT OF SIGNIFICANCE: (3-Aminomethylphenyl)boronic
acid (AMPB)-tethered
hyaluronic acid-
ceramide (HACE)-based nanoparticles (NPs), including
manassantin B (MB), were fabricated and their
tumor targeting and penetration efficiencies were assessed in MDA-MB-231 (CD44 receptor-positive human
adenocarcinoma)
tumor models. MB, which exhibited antitumor efficacies via the inhibition of angiogenesis and
hypoxia inducible factor (HIF)-1, was entrapped in HACE-AMPB NPs in this study.
Phenylboronic acid located in the outer surface of HACE-AMPB/MB NPs (in the aqueous milieu) may react with the
sialic acid over-expressed in
cancer cells and intramolecular B‒O bond can be formed. This
phenylboronic acid-
sialic acid interaction may provide additional
tumor targeting and penetration potentials together with an enhanced permeability and retention (EPR) effect (passive
tumor targeting) and HA-CD44 receptor interaction (active
tumor targeting). Developed HACE-AMPB NP may be one of promising nanocarriers for the imaging and
therapy of CD44 receptor-expressed
cancers.